EKF Diagnostics has launched its upgraded Biosen C-Line benchtop glucose and lactate analyser, designed to meet customer demands for improved connectivity and usability.
The company has also secured contracts with the Hong Kong Red Cross and the Thai Red Cross, totalling approximately £600,000 ($774,700).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Biosen C-Line is a point-of-care (POC) device widely used in healthcare and sports performance settings for the accurate measurement of glucose and lactate levels.
Biosen said the newly enhanced range makes use of the same technology as its predecessor, offering precise measurements in various sample types.
The updates include better connectivity features, making it fully compatible with EKF Link, a middleware solution that facilitates the management of POC analysers on a unified platform.
EKF Link represents a secure way to connect POC devices to hospital and laboratory IT systems, ensuring seamless data transfer from the analyser to relevant databases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEKF Diagnostics executive chair Julian Baines said: “The launch of the new and enhanced Biosen is in line with our strategy to focus our R&D on developing existing, high-growth, high-margin products and we continue to lead and innovate in this space.
“We are also encouraged by the growing demand for EKF Link, which is compatible with the EKF POC portfolio as well as other devices, and has improved our competitive positioning, opening a number of new tender opportunities around the world.”
The addition of EKF Link to the company’s offerings has generated new tender opportunities worldwide, including the contracts with the Hong Kong Red Cross and Thai Red Cross, the company said.
These partnerships are expected to support EKF’s ongoing growth in the global blood bank market.
